REYON Pharmaceutical Co., Ltd. (KRX:102460)
South Korea · Delayed Price · Currency is KRW 10,000
-140 (-1.38%)
At close: Aug 21, 2026
REYON Pharmaceutical Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 183,410 | 197,716 | 235,498 | 303,360 | 384,347 | 631,111 | |
Market Cap Growth | -8.42% | -16.04% | -22.37% | -21.07% | -39.10% | 61.64% |
Enterprise Value | 393,226 | 403,416 | 381,553 | 498,164 | 550,681 | 726,725 |
Last Close Price | 10000.00 | 10780.00 | 12840.00 | 16540.00 | 21444.72 | 34972.84 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 56.73 | 84.66 | 52.23 | 116.61 |
PS Ratio | 1.28 | 1.36 | 1.59 | 2.01 | 2.50 | 4.42 |
PB Ratio | 0.94 | 0.90 | 0.94 | 1.22 | 1.55 | 2.57 |
P/TBV Ratio | 0.94 | 0.90 | 0.95 | 1.23 | 1.56 | 2.59 |
P/OCF Ratio | 29.48 | 135.73 | - | 35.09 | 44.03 | 54.01 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.74 | 2.76 | 2.57 | 3.30 | 3.58 | 5.09 |
EV/EBITDA Ratio | 109.80 | 1736.25 | 71.21 | 76.00 | 61.31 | 117.02 |
EV/EBIT Ratio | - | - | - | 281.00 | 123.81 | 470.45 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 1.05 | 0.98 | 0.82 | 0.91 | 0.85 | 0.85 |
Debt / EBITDA Ratio | - | 930.13 | 38.08 | 34.33 | 23.40 | 33.38 |
Net Debt / Equity Ratio | 1.02 | 0.95 | 0.78 | 0.81 | 0.70 | 0.45 |
Net Debt / EBITDA Ratio | -86.39 | 900.94 | 36.18 | 30.64 | 19.39 | 17.69 |
Net Debt / FCF Ratio | -26.25 | -32.41 | -11.11 | -9.93 | -3.20 | -1.04 |
Asset Turnover | 0.31 | 0.30 | 0.30 | 0.31 | 0.32 | 0.36 |
Inventory Turnover | 2.88 | 2.72 | 1.99 | 2.25 | 2.60 | 2.35 |
Quick Ratio | 0.27 | 0.29 | 0.35 | 0.51 | 1.63 | 2.91 |
Current Ratio | 0.52 | 0.56 | 0.66 | 0.80 | 2.27 | 3.47 |
Return on Equity (ROE) | -17.66% | -12.60% | 1.67% | 1.44% | 3.02% | 2.33% |
Return on Assets (ROA) | -4.55% | -4.09% | -0.12% | 0.22% | 0.58% | 0.24% |
Return on Invested Capital (ROIC) | -8.04% | -7.23% | -0.18% | 0.36% | 1.15% | 0.49% |
Return on Capital Employed (ROCE) | -11.20% | -9.80% | -0.30% | 0.50% | 1.00% | 0.40% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -18.67% | -14.99% | 1.76% | 1.18% | 1.93% | 0.88% |
FCF Yield | 0.64% | -3.27% | -7.41% | -6.67% | -14.16% | -16.68% |
Dividend Yield | - | - | - | 0.91% | 0.70% | 0.71% |
Payout Ratio | - | - | 66.27% | 76.41% | 61.38% | 62.56% |
Buyback Yield / Dilution | -0.76% | 0.15% | -0.15% | -0.46% | -3.03% | -4.05% |
Total Shareholder Return | -0.76% | 0.15% | -0.15% | 0.45% | -2.33% | -3.34% |